BC Extra | Dec 17, 2019
Clinical News

Axsome continues ascent with Phase III success in depression

With its depression therapy meeting in Phase III and plans to submit an NDA next year, Axsome has more than quadrupled its market cap since October, when it received a bump from a Phase II...
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring....
BC Week In Review | Apr 25, 2019
Clinical News

Axsome's AXS-05 meets in Phase II for smoking cessation

Axsome said twice-daily AXS-05 met the primary endpoint of reducing the mean number of cigarettes smoked per day assessed over a 3-week period vs. bupropion in a Phase II trial for smoking cessation (8.49 vs....
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Extra | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
BC Week In Review | Jan 11, 2019
Clinical News

Axsome's AXS-05 meets in Phase II for MDD

Axsome Therapeutics Inc. (NASDAQ:AXSM) added $4.24 (161%) to $6.87 on Jan. 7 after reporting that AXS-05 met the primary endpoint in the Phase II ASCEND trial to treat moderate-to-severe major depressive disorder (MDD). On the...
BC Week In Review | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion....
BC Week In Review | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

Orexigen Therapeutics Inc. (NASDAQ:OREX) said on March 12 it filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an auction sale of substantially all of...
BC Week In Review | Dec 8, 2017
Financial News

Axsome raises $9.5M in direct offering

CNS company Axsome Therapeutics Inc. (NASDAQ:AXSM) raised $9.5 million through the sale of 1.8 million units at $5.33 in a registered direct offering led by HC Wainwright. Each unit represents one share of common stock...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
Items per page:
1 - 10 of 376